An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

PubWeight™: 8.95‹?› | Rank: Top 0.1%

🔗 View Article (PMC 3229841)

Published in Hepatology on September 26, 2011

Authors

Marc G Ghany1, David R Nelson, Doris B Strader, David L Thomas, Leonard B Seeff, American Association for Study of Liver Diseases

Author Affiliations

1: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800, USA. marcg@intra.niddk.nih.gov

Articles citing this

(truncated to the top 100)

Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25

Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology (2013) 3.54

The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol (2013) 2.60

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46

Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging (2013) 2.22

Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19

Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut (2013) 1.88

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med (2014) 1.86

Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol (2012) 1.85

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63

IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med (2014) 1.61

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57

Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep (2014) 1.55

Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) (2014) 1.53

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43

New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30

Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol (2012) 1.30

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology (2012) 1.24

Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17

Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis (2013) 1.15

Barriers to hepatitis C treatment. Liver Int (2012) 1.13

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon (2012) 1.12

Screening for HCV infection in jails. JAMA (2012) 1.11

The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis (2012) 1.10

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep (2014) 1.10

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology (2012) 1.09

Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? J Gastroenterol (2013) 1.08

The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots. PLoS One (2015) 1.07

Emerging therapies for hepatitis C. Gut Liver (2014) 1.07

Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol (2012) 1.06

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother (2013) 1.04

Hepatitis C virus in pregnancy. Am J Perinatol (2013) 1.03

Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol (2013) 1.02

A review of the epidemiological and clinical aspects of West Nile virus. Int J Gen Med (2014) 1.02

Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog (2013) 1.02

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01

Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01

Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99

Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99

Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health (2014) 0.99

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99

Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98

Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes. J Clin Microbiol (2012) 0.97

Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol (2015) 0.96

The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol (2013) 0.96

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon (2011) 0.96

Hepatitis C virus genetic variability and evolution. World J Hepatol (2015) 0.96

Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat (2012) 0.95

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother (2014) 0.95

Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95

Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol (2014) 0.94

Hepatitis C virus genotypes and association with viral load in yazd, central province of iran. Hepat Mon (2014) 0.94

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93

Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis (2013) 0.93

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study. Antimicrob Agents Chemother (2013) 0.93

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol (2015) 0.92

Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol (N Y) (2012) 0.92

Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92

Systematic analysis of enhancer and critical cis-acting RNA elements in the protein-encoding region of the hepatitis C virus genome. J Virol (2013) 0.91

Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol (2013) 0.91

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother (2013) 0.91

Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy. Dig Dis Sci (2016) 0.91

Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer (2013) 0.91

Recent trends in the treatment of chronic hepatitis C. Korean J Hepatol (2012) 0.90

Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90

Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr (2013) 0.90

Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med (2013) 0.89

Telaprevir experience from Turkey. Hepat Mon (2015) 0.89

Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol (2012) 0.88

Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol (2013) 0.88

IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat (2013) 0.88

Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis (2012) 0.88

Current progress in the treatment of chronic hepatitis C. World J Gastroenterol (2012) 0.87

Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol (2014) 0.87

Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). BMC Infect Dis (2012) 0.87

Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence (2012) 0.86

NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A (2013) 0.86

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One (2012) 0.86

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother (2012) 0.86

Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol (2012) 0.85

Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrol (2012) 0.85

Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC. Dig Dis Sci (2013) 0.85

Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PLoS One (2014) 0.85

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother (2012) 0.85

Computer aided screening of Accacia nilotica phytochemicals against HCV NS3/4a. Bioinformation (2013) 0.85

Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health (2014) 0.84

Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med (2012) 0.84

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One (2014) 0.84

Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol (2014) 0.84

Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol (2012) 0.84

Hepatocyte nuclear factor 4α and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus. J Virol (2013) 0.84

Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) (2015) 0.84

Articles cited by this

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (2010) 6.52

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53

Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med (2003) 4.15

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72

Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology (2010) 2.87

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol (2013) 1.40

American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology (1995) 1.11

Articles by these authors

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62

The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science (2007) 11.15

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22

The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Protection against persistence of hepatitis C. Lancet (2002) 5.94

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

Primary biliary cirrhosis. Hepatology (2009) 5.35

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

The Ectocarpus genome and the independent evolution of multicellularity in brown algae. Nature (2010) 3.60

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (2013) 3.40

Natural history of hepatitis C. Clin Liver Dis (2005) 3.34

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18

Hepatitis C and progression of HIV disease. JAMA (2002) 3.15

Genetic drift at expanding frontiers promotes gene segregation. Proc Natl Acad Sci U S A (2007) 3.14

The Selaginella genome identifies genetic changes associated with the evolution of vascular plants. Science (2011) 3.10

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

Orientation discrimination of single-stranded DNA inside the alpha-hemolysin membrane channel. Proc Natl Acad Sci U S A (2005) 3.06

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06

IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02

In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00

Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99

The African coelacanth genome provides insights into tetrapod evolution. Nature (2013) 2.78

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Virus shapes and buckling transitions in spherical shells. Phys Rev E Stat Nonlin Soft Matter Phys (2003) 2.74

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61

Needlestick transmission of hepatitis C. JAMA (2002) 2.55

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

Genomic analysis of detoxification genes in the mosquito Aedes aegypti. Insect Biochem Mol Biol (2007) 2.38

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30

The genome of Nectria haematococca: contribution of supernumerary chromosomes to gene expansion. PLoS Genet (2009) 2.29

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24

An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23

Direct visualization of dislocation dynamics in grain-boundary scars. Nat Mater (2005) 2.22

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20

High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20

Gene surfing in expanding populations. Theor Popul Biol (2007) 2.19

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19

Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14

Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06

DNA unzipped under a constant force exhibits multiple metastable intermediates. Proc Natl Acad Sci U S A (2003) 2.06

Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med (2011) 2.04

Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02

Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril (2002) 1.97

Foldable structures and the natural design of pollen grains. Proc Natl Acad Sci U S A (2010) 1.97

Single molecule statistics and the polynucleotide unzipping transition. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.94

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92

Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92

Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85

Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83

HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82

Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80

C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet (2002) 1.80

A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80

Sexual dysfunction in men undergoing infertility evaluation: a cohort observational study. Fertil Steril (2003) 1.76

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75

Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66

Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril (2003) 1.66

Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65

Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65

Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62